CClinicalTrials.gg
Not yet recruitingNCT07367646Updated Apr 24, 2026

Development of Multidimensional Screening Tool for WMSDs

An observational study in Work-Related Musculoskeletal Disorders, Musculoskeletal Diseases and Occupational Diseases, sponsored by Sahmyook University. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Sahmyook University · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
250
Ages
19 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to develop a multidimensional screening tool for Work-Related Musculoskeletal Disorders (WMSDs) and to evaluate its psychometric properties. The study involves a cross-sectional survey of approximately 250 workers in the bio-pharmaceutical industry to assess the tool's structural validity, internal consistency, construct validity, and measurement invariance following COSMIN guidelines.

Read the detailed description

Work-related musculoskeletal disorders (WMSDs) are a major occupational health issue. While various screening tools exist, few comprehensively assess red flags (signs of serious pathology), yellow flags (psychosocial risk factors), and physical symptoms specifically for industrial workers. This study aims to address this gap by developing a new screening tool and validating its reliability and validity. The study design follows the COSMIN (COnsensus-based Standards for the selection of health Measurement INstruments) checklist. The validation process involves a cross-sectional survey targeting 250 workers, including both office and production staff. The developed tool is designed to screen for serious medical conditions (Red flags) requiring referral, as well as to assess physical symptoms and psychosocial barriers (Yellow flags). Psychometric evaluation will specifically focus on the physical and psychosocial domains, as Red flags are typically binary screening items. Key psychometric properties to be evaluated include: 1. Structural Validity: Confirmatory Factor Analysis (CFA) will be conducted to verify the factor structure of the physical and psychosocial domains. 2. Internal Consistency: Cronbach's alpha coefficients will be calculated for these subscales. 3. Measurement Invariance: Multi-group CFA will be performed to ensure the tool functions equivalently across different job types (office vs. production). 4. Construct Validity: Correlations with established instruments (e.g., OSPRO-YF, FABQ, TSK) will be analyzed. The ultimate goal is to provide a practical and scientifically validated instrument for the early detection, triage, and management of WMSDs in workplace settings. 5. Cut-off Determination: ROC analysis will be conducted to establish optimal cut-off scores for identifying high-risk groups (Yellow flags), using established tools as a reference.

02

Conditions studied

  • Work-Related Musculoskeletal Disorders
  • Musculoskeletal Diseases
  • Occupational Diseases

Keywords

  • WMSDs
  • Musculoskeletal Pain
  • Screening Tool
  • Psychometrics
  • Occupational Health
03

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of workers currently employed at a bio-pharmaceutical company (Samsung Biologics) in South Korea. This includes both office workers engaged in VDT tasks and production workers involved in physical tasks who report musculoskeletal symptoms.

Inclusion criteria

  • Current regular employees working at the study site.
  • Adults aged 19 years or older who understand the study purpose and procedures and voluntarily agree to participate in writing.
  • Participants capable of reading, understanding, and self-responding to the questionnaire.
  • Individuals with musculoskeletal symptoms according to NIOSH standards: symptoms lasting more than one week OR recurring at least once a month in the past 12 months (symptoms include pain, aching, stiffness, burning sensation, tingling, or numbness).

Exclusion criteria

Exclusion Criteria:

  • Individuals with cognitive or mental impairments that make it difficult to understand the study or complete the survey.
  • Individuals suspected of having a medical emergency or severe disease requiring immediate medical attention.
  • Individuals deemed unsuitable for participation by the researcher.
04

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Bio-pharmaceutical Industry Workers

    Workers currently employed at Samsung Biologics, including both office and production staff, who meet the inclusion criteria for musculoskeletal symptoms.

    Other: Survey Administration

Interventions

  • OtherSurvey Administration

    Participants will complete the newly developed multidimensional screening tool and standard validation questionnaires (e.g., OSPRO-YF, FABQ, TSK) to assess musculoskeletal symptoms and psychosocial factors.

05

What researchers measure

Primary outcomes

  1. Structural Validity

    Evaluated using Confirmatory Factor Analysis (CFA). Model fit will be assessed based on stricter criteria: CFI ≥ 0.95, TLI ≥ 0.95, RMSEA ≤ 0.06, and SRMR ≤ 0.08 (Hu \& Bentler, 1999). If model fit is insufficient, modification indices (MI) will be used to adjust the model within theoretically justifiable limits.

    Time frame: Baseline

Secondary outcomes

  1. Internal Consistency

    Assessed using Cronbach's alpha coefficients for each factor. A value between 0.70 and 0.90 is considered to indicate appropriate internal consistency (Tavakol \& Dennick, 2011).

    Time frame: Baseline

  2. Measurement Invariance

    Evaluated using Multi-group CFA between office workers (VDT tasks) and production workers (physical tasks). Invariance is determined based on criteria such as ΔCFI ≤ 0.01 and ΔRMSEA ≤ 0.015 (Chen, 2007).

    Time frame: Baseline

  3. Construct Validity

    Assessed by analyzing correlations (Pearson or Spearman) between the developed tool and standard instruments. A correlation coefficient (r) of ≥ 0.50 represents adequate convergent validity.

    Time frame: Baseline

  4. Cut-off Determination for Yellow Flags

    Receiver Operating Characteristic (ROC) analysis will be conducted to establish optimal cut-off scores for identifying high-risk groups (Yellow flags). Established instruments (e.g., OSPRO-YF) will be used as a reference to calculate sensitivity, specificity, and the Youden index.

    Time frame: Baseline

06

Study locations

1 site
  • Samsung Biologics
    Incheon, 21987, South Korea
07

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect the privacy and confidentiality of the participants.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07367646
Lead sponsor
Sahmyook University
Responsible party
Kibum Jung (Ph.D. Candidate, Sahmyook University) — Principal investigator
First posted
Jan 26, 2026
Start date
Jun 20, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 24, 2026

Study contacts

Kibum Jung, Master of Science
Contact
kibum921031@gmail.com
+82 10-9899-3276

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion